chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The patient was brought to the ED by EMS on 9/12/23 for altered mental status. At his nursing home, staff that day noticed the patient acutely became confused. EMS noted the patient was desaturating to 88% on room air, so was placed on 4L nasal cannula. Ultimately, the patient was admitted on 9/12 for pneumonia. A COVID PCR test performed also resulted positive. He was eventually found to have metabolic encephalopathy due to COVID pneumonia. Palliative care was consulted on 9/14, and due to his chronic deterioration, it was agreed that patient should go to comfort cares. The patient passed away on 9/27/23. Of note, he had received the primary COVID vaccine series and three boosters.
2-4" red indurated coin like plaque. Raised tender to touch at site of varicella injection. Treated with clindamycin. Resolved in 1 week.
Left-sided chest pain and tightness  onset in evening 4/16.  Able to sleep, still there when he woke 4/17.   Spread to  left arm.  Denies Reflux.  Mom thinks ALKA Seltzer helped. Xopenex did not help. Sharp pain at end-expir- ation. Hurt to lay on that side. Resting Improving
Right arm to elbow area, redness and warmth with palpable nodule right deltoid region commenced late 2/21/07 subsiding symptoms at time of report.
Red, swollen, tender. Started 8/25/10. Came into clinic on 9/7/10. Saw Dr. Plan is: BENADRYL.
Mouth was sensitive to things; Little bumps here and there; This spontaneous case was reported by a consumer and describes the occurrence of ORAL PAIN (Mouth was sensitive to things) and ORAL DISORDER (Little bumps here and there) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 021B21A and 037B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included CELECOXIB (CELEXA [CELECOXIB]) for an unknown indication.   On 03-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-May-2021, the patient experienced ORAL PAIN (Mouth was sensitive to things) and ORAL DISORDER (Little bumps here and there). At the time of the report, ORAL PAIN (Mouth was sensitive to things) and ORAL DISORDER (Little bumps here and there) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient reported that her friend recommended "some natural thing" for the immune system, but it didn't work.   This case was linked to MOD-2021-269633 (Patient Link).
he had an infection; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP), Program ID.  A male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INFECTION (hospitalization), outcome "unknown", described as "he had an infection". Clinical course as followed: Caller mentioned that she took the Pfizer COVID-19 Vaccine and she forced her parents to take it, her father was a healthy man and all of the sudden from one night to another he's in the hospital. He had an infection and they're kind of looking towards his heart. He did not have problems at all before.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Developed respiratory distress, hypertensive emergency, and acute congestive heart failure with bilateral edema of lower legs
Patient has exp swelling size of a pea, irritation and black hairs growing where the incision was located. She stated she isn't certain of the exact date when the signs started. On 10/28/2020 is when she noticed the black hairs growing from the vaccination site.
Fever up to 102 (oral), nausea with vomiting X 1 and hives. Treated with prednisone.
On 11/04/2000, the patient experienced 3 pox-like lesions and low grade fever. On 11-10-2000, the patient reported to her physician that she had "increased symptoms", severity or change unknown. Additional information has been requested.
I went to the Dermatologist to get my skin checked out and I asked her to look at an unfamiliar bump at the side of my nose. She biopsied the pump. I've never had any medical event prior to this. I have radiation starting next week.
Patient developed hives on arms and hands minutes after immunization. Treated with diphehydarmine and began to improve.
General malaise; Neck is painful to touch; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (General malaise), NECK PAIN (Neck is painful to touch) and FATIGUE (Fatigue) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (General malaise), NECK PAIN (Neck is painful to touch) and FATIGUE (Fatigue). At the time of the report, VACCINATION COMPLICATION (General malaise), NECK PAIN (Neck is painful to touch) and FATIGUE (Fatigue) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications was not reported.  Treatment medications was not reported.
Presented with acute, highly pruritic urticaria covering over 20% of body approximately 10 days after receipt of COVID-19 booster (Moderna), requiring one course of oral steroids as well as benadryl, extra doses of zyrtec, and pepcid (in addition to baseline zyrtec, singulair and adviar).  Acute urticaria possibly related to to exposure to a new laundry detergent; however, no history of this type or severity of allergic reaction with skin presentation.  Rash started partially resolving after approximately 1 week of onset; however migratory, pruritic urticarial rash persists for months after 3rd dose (booster) of Moderna COVID vaccine, and characterized by dermatographia (unresolved at the time of the report).  No known exposure to allergens, and  cause for persistent rash and dematographia unknown.
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) in a 28-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2022 at 1:03 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 05-Feb-2022 at 1:03 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not reported.  The patient's ethnicity was provided as private.  A Series of patients approx. 540 patients received lot number 066H71A past its 30 days expired date. Vaccines went into 2-8 degree Celsius thaw state on or above 24-Dec-2021. This vaccine was administered up until its Mfg Exp date of 04-Apr-2022.   Treatment information was not provided.
20 minutes after shot, right side of face started to tingle and went numb  Numbness wore off somewhat after about an hour, but it is still there a little bit
Within 12 hrs temp > 103 during the night after IMM given. Mom had treated with ibuprofen. Next day temp 103 counselled pt to to to ER. Unable to speak with parents.
Reports anxiety and feeling "like I had COVID" immediately after vaccine. Reports has had anaphylaxis symptoms since vaccine, has had them every day. These are redness, hives and swelling of random areas of skin on her body which will last 15 minutes (showed me a picture of fairly substantial lower lip edema). Since vaccine has also noted chest pain and palpitations like it will "skip a beat" and then has chest tightness. Pain lasts a few seconds, tightness lasts 10 minutes or so.  Loud systolic cardiac murmur noted on exam, loudest at left sternal border, reports had a murmur as a child but has not been told she has one since and comes to the doctor every few months for various things.
Itching that started in the area of the injection and then itching all over. No rashes, no fever. No other associated symptoms. Given Benadryl with some relief.
Experienced odd numbness; This is a spontaneous report from a contactable consumer or other non-Health Care Professional. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number and Expiry date: Unknown), via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunization. The patient medical history was not reported. The patient's concomitant medications were not reported. On an unspecified date the patient experienced odd numbness. On an unspecified date in 2021, the patient had recovered from the event.  Information on batch/lot number has been requested. ; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021766717 Same Vaccine/event, different  patient
Pt noted numbness, tingling in fingers of the right hand on 01/07/2002. He visits the ER four times during the next few days after the immunizations. Admitted to the hospital on 01/13/2002. He also noted that the was unable to walk, could not open hands nor move fingers, difficulty swallowing. Pt was diagnosed with Guillian Barre syndrome.
Patient states that shot was given in lower deltoid in an area not cleaned with alcohol and she developed cellulitis in the area 2 days later.  This is being treated with cephalexin
A few hours after vaccination patient reported feeling numbness in his arm and hand. He says this feeling improved the next day without treatment but has worsened again and not improved since.  He has not sought any treatment or used any medication at this time but still has a numb feeling in the arm and hand.
G62.9 NEUROPATHY 4/27/2023 CHF (CONGESTIVE HEART FAILURE), UNSPECIFIED I26.99 ACUTE PULMONARY EMBOLISM 4/25/2023 CHF (CONGESTIVE HEART FAILURE), UNSPECIFIED
Sick sinus syndrome. ED visit to hospital admission. This visit was within 6 weeks of receiving the COVID vaccine.
Patient noted soreness, redness and swelling at injection site that persisted for several days. No further treatment was needed.
After administration of varicella #2, child had tearing of both eyes and vomited. His eyelids became pink and swollen. He had no trouble breathing and was given Benadryl with no further event.
and a pain and swelling on her left foot; and a pain and swelling on her left foot; She also felt warm.; joint pain; swelling that radiated from her arch; the mark was still there on 18May2021 but the area is wider but lighter; exhibiting slight pain on scale of 1 to 4 time to time; This is a spontaneous report from a contactable consumer. A 55-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE: Solution for injection; Batch/Lot Number: FW0168) via an unspecified route of administration, administered in Arm Right on 18May2021 as 2ND DOSE, SINGLE DOSE for covid-19 immunization. Medical history included diabetic. There were no concomitant medications. The patient previously received first dose of BNT162B2 (Batch/Lot Number: EW0172) on 26Apr2021 for covid-19 immunization and experienced dark marking over arch on side of foot. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. As after first dose she reported having a darkening and dark marking on her arch on the side of her left foot and after 2nd dose the mark was still there on 18May2021 but the area was wider but lighter and a pain and swelling on her left foot, with the pain level of 4 out of 10. She also felt warm. She also mentioned being diabetic and never having a problem on her feet before. Her HCP said that she would be undergoing tests. She also reiterated that joint pain was not same as foot pain and that her side effect should not be reported under joint pain. Reporter wanted to ask if these side effects have been reported yet. Reporter stated she got the second shot on 18May2021 and the mark was still there but maybe a week in a half after that she started exhibiting slight pain on scale of 1 to 4 time to time, swelling that radiated from her arch and it felt warm. Reporter also reported that, she went to see a podiatrist and she was prescribing a venous doppler to check it out. she wanted to notate this and how she had no issues with her feet previously. Patient stated felt warm started a week in a half after 18May2021. All events occurred in an unknown date in May2021. Patient visited to clinic. Patient stated she has taken Ibuprofen as treatment for felt warm, but she did not want to take it every day. The outcome of the events She also felt warm, swelling that radiated from her arch and exhibiting slight pain on scale of 1 to 4 time to time was not recovered and for other events was unknown  Follow up needed, further information was requested.
This spontaneous report as received from a Certified Medical Assistant (CMA) refers to multiple unknown patients of unknown age. On an multiple unknown dates, these patients were vaccinated with VAQTA (lot # M015290, Expiration Date: 20-SEP-2017). It was called because of Digital Data Logger. These vaccines were stored under 1.2 degree Celsius for one hour. There was no temperature excursions. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Rash on left ear, side of face, forehead, right chin.  left eye swollen, slight itchiness
pt hearing impaired; approx 7 days p/vax pt exp loss of hearing; pt also devel localized redness at inject site; prickly heat type rash on stomach & chest; mom noticeD on 6/19/98 an apparent increase in hearing difficulty;
Acute Immune-mediated Demyelinating Polyneuropathy; This is a literature report for the following literature source(s).  A 36-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "progressive bilateral paresthesia" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19-vaccine (DOSE 1, MANUFACTURER UNKNOWN), for COVID-19 immunisation. The following information was reported: DEMYELINATING POLYNEUROPATHY (medically significant), 1 week after the suspect product(s) administration, outcome "recovering", described as "Acute Immune-mediated Demyelinating Polyneuropathy". The patient underwent the following laboratory tests and procedures: Antibody test: unremarkable; unremarkable; unremarkable; unremarkable; negative, notes: for serum and CSF; Antineutrophil cytoplasmic antibody: unremarkable; Antinuclear antibody: unremarkable; positive; Bacterial test: which included hepatitis, notes: serologies,Campylobacter jejuni serology, Lyme atb, CMV atb, EBV atb were all negative; Blood folate: Normal; Cytomegalovirus test: negative, notes: for serum and CSF; Double stranded DNA antibody: unremarkable; Electromyogram: showed evidence of acute diffuse sensorimotor, notes: neuropathy with mixed axonal and demyelinating features; Epstein-Barr virus antibody: negative, notes: For serum and CSF; Helicobacter test: negative, notes: in serum and CSF; Hepatitis viral test: negative, notes: in serum and CSF; clinical features: not suggestive of Sjogren's Syndrome.; unremarkable; which included hepatitis, notes: serologies,Campylobacter jejuni serology, Lyme atb, CMV atb, EBV atb were all negative; not suggestive of Sjogren's Syndrome.; Magnetic resonance imaging head: showed small scattered foci of increased FLAIR, notes: signal in the white matter, suggesting an underlying inflammatory process; Neurological examination: normal; Orthopaedic examination: normal; Physical exam: was notable for decreased distal sensation to, notes: touch and pain in all 4 limbs, otherwise, the rest of her neurological and musculoskeletal evaluation was normal; Rheumatoid factor: unremarkable; Vitamin B1: Normal; Vitamin B12: normal. Therapeutic measures were taken as a result of demyelinating polyneuropathy.; Sender's Comments: As there is limited information in the case provided, the causal association between the reported events DEMYELINATING POLYNEUROPATHY and the suspect drug cannot be excluded. The case will be reassessed once new information is available.
Symptoms: Fever, nausea, headache, vomiting  Started: 1/26/21 @ 00:00 with fever, progressed to headache and vomiting throughout morning until ~ 12:00 noon, headache continued until 1/27/21 a.m. Treatment: sleep, tylenol
Became significantly ill with influenza-like symptoms the day following #1 vaccination.    So ill that had I been required to work,  I would have been unable to do so.    But the real problem that causes me to report this vaccine is that following the #2 shot in the series,  I have had unexplained "generalized muscle pain"  and a significant increase in "ringing in the ears"   ( note:  I do have mild tinnitus of long standing).    I also feel at times as if I could become nauseated.    And this has been occurring DAYS since the #2 vaccination that was performed at another pharmacy on 11/21/2019.   Lot code for the #2 dose was the same:   58160-0823-11
pt reported symptoms to her today, but may have had symptoms since after visit to clinic on 10/14/22. Received multiple vaccines during visit. States per picture pt sent her it is very bright, swollen, and inflamed, also appears raised. Pt was at school today. Mother states she had him go to the school nurse who "outlined" the rash with a marker to monitor spread. School nurse sent pt home. Mother had pt take Claritin and go to the neighbor's house to be monitored there while she is at work. Pt told her the rash is painful.   Plan: F/U at UC ASAP, pt will have neighbor take son to UC. Review given to provider there who is happy to see pt and will contact mother via phone if needed. Advised to have pt go to the ED if he develops any chest pain, SOB, severe HA/vision change. UC provider advised will be closed for lunch from 1-2pm, pt can come before or after. Mother will have pt come to UC at 2pm.    Disposition recommended: Seek medical care within 2 hours   Patient agrees with disposition and plan: yes; mother verbalizes understanding of plan, will notify pt. Thankful for today's call-back.
Large, red, hot bump appeared on 12/6/21. Larger on 12/7/21. Started itching around 5pm on 12/7/21.
the patient came in this morning for the bivalent updated moderna vaccine , I adminsterd the regular moderna , I spoke with the patient over the phone she is planning to come back after 2 months for the correct bivalent moderna
Information has been received from a physician concerning a 2 year old female who on 23 April 2004, was vaccinated subcutaneously with a 0.5 ml dose of varicella virus vaccine live (Oka/Merck) (Lot #647087/0851N). The physician reported that on 02 February 2006, the patient presented to the physician's office with breakthrough chickenpox characterized by lesions at various stages. The physician also reported that the patient also had nasopharyngitis at the time of her breakthrough chickenpox. At the time of this report, the outcome was unknown. Additional information has been requested.
pt recv vax in OCT96 & 14DEC96 pt devel flu sx for 2wk;28DEC96 pt devel a fever blister;pt was seen by MD & ATB were prescribed;pt has recovered;pt indicated had been vaccinated w/one of the recalled lots, but was unable to ID specific lot
black stool; diarrhea that is watery and charcoal colored/diarrhea very frequent; not eating; This spontaneous case was reported by a consumer and describes the occurrence of FAECES DISCOLOURED (black stool), DIARRHOEA (diarrhea that is watery and charcoal colored/diarrhea very frequent) and DECREASED APPETITE (not eating) in an 89-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 045C21A and 939902) for COVID-19 vaccination.     No Medical History information was reported.  Concomitant products included HYDROCHLOROTHIAZIDE and PRAVASTATIN for an unknown indication.   On 26-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Oct-2021, the patient experienced FAECES DISCOLOURED (black stool), DIARRHOEA (diarrhea that is watery and charcoal colored/diarrhea very frequent) and DECREASED APPETITE (not eating). The patient was treated with BISMUTH SUBSALICYLATE (PEPTO BISMOL [BISMUTH SUBSALICYLATE]) for Adverse event, at an unspecified dose and frequency. At the time of the report, FAECES DISCOLOURED (black stool), DIARRHOEA (diarrhea that is watery and charcoal colored/diarrhea very frequent) and DECREASED APPETITE (not eating) had not resolved.